Sebia announced it has received FDA 510(k) clearance for its free light chain kappa and lambda assays, intended to aid in diagnosing and monitoring patients who have multiple myeloma or immunoglobulin light chain amyloidosis.
Read More »Sebia acquires Zeus Scientific
December 2022—Sebia announced the acquisition of Zeus Scientific, an in vitro diagnostic company based in Branchburg, NJ. Sebia, headquartered in Lisses, France, says the acquisition will expand its capabilities and product portfolio in autoimmunity and reinforce its operations and footprint in the United States. Financial terms of the agreement are undisclosed.
Read More »Sebia acquires Zeus Scientific
Oct. 17, 2022—Sebia announced the acquisition of Zeus Scientific, an in vitro diagnostic company based in Branchburg, NJ.
Read More »sFLC assays for multiple myeloma testing, 5/18
May 2018—Sebia launched two CE-marked serum free light chain assays, Sebia FLC Kappa and Sebia FLC Lambda, for multiple myeloma testing. The two assays aim to provide more consistent results by overcoming the challenges in analytical performance and coherence encountered in current testing methods.
Read More »FDA OKs Hydrashift 2/4 daratumumab, 4/18
April 2018—Sebia received FDA 510(k) clearance for its Hydrashift 2/4 daratumumab assay, intended to be used with Hydragel IF, for the qualitative detection of monoclonal proteins in human serum by immunofixation electrophoresis.
Read More »FDA clears Sebia Hydrashift 2/4 daratumumab assay
Feb. 26, 2018—Sebia announced it has received FDA 510(k) clearance for its Hydrashift 2/4 daratumumab assay, intended to be used with Hydragel IF, for the qualitative detection of monoclonal proteins in human serum by immunofixation electrophoresis. This in vitro diagnostic reagent mitigates the daratumumab-mediated interference seen in immunofixation results for patients with multiple myeloma treated with Darzalex (daratumumab), a fully ...
Read More »